- $1.70m
- $0.09m
- $19.48m
- 50
- 70
- 35
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -98.23% | ||
| Return on Equity | -151.96% | ||
| Operating Margin | -12.13% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.88 | 44.48 | 35.4 | 24.16 | 19.48 | 21.58 | 23.74 | -3.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
Directors
- Martin Sumichrast CHM (55)
- Raymond Coffman CCE (60)
- T. Ronan Kennedy CFO (43)
- Francisco Mangual SVP (43)
- David Johnson SVP (52)
- Matthew Coapman CMO (46)
- Sibyl Swift VPR (41)
- Lance Blundell GCN (51)
- Peter Ghiloni IND (71)
- William Raines IND (62)
- Bakari Sellers IND (37)
- Scott Stephen IND (56)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 17th, 2015
- Public Since
- November 17th, 2017
- No. of Shareholders
- 13,308
- No. of Employees
- 42
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 6,262,833
- Address
- 8845 Red Oak Blvd, CHARLOTTE, 28217-5593
- Web
- https://www.cbdmd.com/
- Phone
- +1 7044453060
- Auditors
- Cherry Bekaert LLP
Upcoming Events for YCBD
cbdMD Inc Annual Shareholders Meeting
Q2 2025 cbdMD Inc Earnings Release
Q3 2025 cbdMD Inc Earnings Release
Similar to YCBD
Can Fite Biopharma
NYSE MKT
China Pharma Holdings
NYSE MKT
NovaBay Pharmaceuticals
NYSE MKT
Protalix Biotherapeutics
NYSE MKT
Scorpius Holdings
NYSE MKT
FAQ
What is the cbdMD share price?
As of Today at 18:49 UTC, shares in cbdMD are trading at $0.27. This share price information is delayed by 15 minutes.
How has the cbdMD share price performed this year?
Shares in cbdMD last closed at $0.27 and the price had moved by -63.84% over the past 365 days. In terms of relative price strength the cbdMD share price has underperformed the S&P500 Index by -66.61% over the past year.
What are the analyst and broker recommendations for cbdMD?
The overall consensus recommendation for cbdMD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the cbdMD dividend yield?
cbdMD does not currently pay a dividend.
Does cbdMD pay a dividend?
cbdMD does not currently pay a dividend.
When does cbdMD next pay dividends?
cbdMD does not currently pay a dividend.
How do I buy cbdMD shares?
To buy shares in cbdMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of cbdMD?
As of the previous close price of $0.27, shares in cbdMD had a market capitalisation of $1.70m.
Where are cbdMD shares listed?
Here are the trading details for cbdMD:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: YCBD
What kind of share is cbdMD?
Based on an overall assessment of its quality, value and momentum cbdMD is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a cbdMD share price forecast for 2025?
The analyst consensus target price for shares in cbdMD is $2.00. That is 638.01% above the last closing price of $0.27.
Analysts covering cbdMD currently have a consensus Earnings Per Share (EPS) forecast of -$0.49 for the next financial year.
Find out moreWhat is the trend in the cbdMD share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like cbdMD. Over the past six months, its share price has underperformed the S&P500 Index by -41.2%.
As of the last closing price of $0.27, shares in cbdMD were trading -45.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the cbdMD PE Ratio?
The cbdMD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of cbdMD?
cbdMD's management team is headed by:
- Martin Sumichrast - CHM
- Raymond Coffman - CCE
- T. Ronan Kennedy - CFO
- Francisco Mangual - SVP
- David Johnson - SVP
- Matthew Coapman - CMO
- Sibyl Swift - VPR
- Lance Blundell - GCN
- Peter Ghiloni - IND
- William Raines - IND
- Bakari Sellers - IND
- Scott Stephen - IND